Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants.

PloS one - 22 May 2009

Prabakaran Mookkan, Prabhu Nayana, He Fang, Hongliang Qian, Ho Hui-Ting, Qiang Jia, Meng Tao, Goutama Michael, Kwang Jimmy

Abstract excerpt

BACKGROUND: Given that there is a possibility of a human H5N1 pandemic and the fact that the recent H5N1 viruses are resistant to the anti-viral drugs, newer strategies for effective therapy are warranted. Previous studies show that single mAbs in immune prophylaxis can be protective against H5N1 infection. But a single mAb may not be effective in neutralization of a broad range of different strains of H5N1 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Viral
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunization, Passive

Share to Influenza A Virus, H5N1 Subtype

Share to Neutralization Tests

Share to Orthomyxoviridae Infections

Share to Reassortant Viruses

Source

Open in PubMed Open full text

Identifiers

PMID: 19478856
DOI: 10.1371/journal.pone.0005672
PMCID: PMC2682562

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants.PMID 19478856Read ↗

A Low-Dose Triple Antibody Cocktail Against the Ectodomain of the Matrix Protein 2 of Influenza A Is A Universally Effective and Viral Escape Mutant Resistant Therapeutic AgentSemantic proximity Read ↗

Synergistic Adaptive Mutations in the Hemagglutinin and Polymerase Acidic Protein Lead to Increased Virulence of Pandemic 2009 H1N1 Influenza A Virus in MiceSemantic proximity Read ↗

Elicitation of protective immune responses using a bivalent H5N1 VLP vaccineSemantic proximity Read ↗

Characterization of Novel Cross-Reactive Influenza B Virus Hemagglutinin Head Specific Antibodies That Lack Hemagglutination Inhibition Activity.Semantic proximity Read ↗

Monoclonal antibodies targeting the influenza virus N6 neuraminidaseSemantic proximity Read ↗

Generation of neutralizing and non-neutralizing monoclonal antibodies against H7N9 influenza virus.Semantic proximity Read ↗

Synergistic PA and HA mutations confer mouse adaptation of a contemporary A/H3N2 influenza virus.Semantic proximity Read ↗

Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape MutantsSemantic proximity Read ↗

Epitope characterization of the protective monoclonal antibody VN04-2 shows broadly neutralizing activity against highly pathogenic H5N1.Semantic proximity Read ↗

Cross-Protective Efficacy of Influenza Virus M2e Containing Virus-Like Particles Is Superior to Hemagglutinin Vaccines and Variable Depending on the Genetic Backgrounds of MiceSemantic proximity Read ↗

Cross-reactive antibodies binding to H4 hemagglutinin protect against a lethal H4N6 influenza virus challenge in the mouse modelSemantic proximity Read ↗

A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.